Hesperadin hydrochloride

Hesperadin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8598. [Abstract]

Customer Validation
Cytosolic (Cyto) and nuclear (Nuc) fractions derived from DLD1 and SW620 cells stimulated with 20 μM of Hesperadin for 8 h were immunoblotted for indicated proteins. PARP1 and Caspase-3 served as loading controls and nuclear/cytosolic markers, respectively. Shown are the representative results from three independent experiments. Hesperadin treatment accelerated TRIM24 translocation to the nucleus and attenuated β-catenin accumulation in the cytosol and its nuclear distribution.

Hesperadin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8598. [Abstract]

Customer Validation
DLD1, SW620, RKO, and SW1643 cells were grown in the absence or presence of Hesperadin at the indicated concentrations for 7 days, then fixed and stained for colony-formation assessment. The colony formation assays revealed that Hesperadin markedly suppressed the proliferation of DLD1 and SW620 cells.

Hesperadin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8598. [Abstract]

Customer Validation
Upper: A schematic diagram of the experimental timeline for the subcutaneous xenograft assay (n = 4 mice per group). Bottom: The tumor growth curve of the mice subcutaneously injected with DLD1 or SW1643 cells after intraperitoneal administration of Hesperadin (2.5 mg/kg; once every other day, for a total of 9 times) or PBS. Representative pictures of tumors dissected from mice at day 24 post-implantation. Scale bar, 1 cm. The results showed that Hesperadin administration showed no impact on tumor growth in mice inoculated with SW1643 cells, it significantly suppressed tumor growth in mice inoculated with DLD1 cells.

Hesperadin hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8598. [Abstract]

Customer Validation
Left: Tumor tissues collected from mice subcutaneously injected with DLD1 or SW1643 cells after intraperitoneal administration of Hesperadin (2.5 mg/kg; once every other day, for a total of 9 times) or PBS were subjected to PCNA staining, with nuclei counterstained by hematoxylin. Scale bar, 50 µm. Right: PCNA staining intensity was quantified in randomly selected fields (n = 5, 6, 8, and 6 for the four histograms, respectively) using ImageJ with the H-DAB color deconvolution vector, and relative intensity was calculated after normalization to the PBS control group. Immunohistochemical staining of PCNA indicated that Hesperadin administration inhibited cell proliferation in tumors formed by DLD1 cells but not in those by SW1643 cells.

Hesperadin hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(11):e2414518. [Abstract]

Customer Validation
Evaluation of the synergistic treatment efficacy of diselenide bonds and Hesperadin (0.07 µg/mL; 16 h).

Hesperadin hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(11):e2414518. [Abstract]

Customer Validation
Effects of different treatments on apoptosis of AC16 cells subjected to OGD/R. Hesperadin (0.07 µg/mL; 16 h).

Hesperadin hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(11):e2414518. [Abstract]

Customer Validation
Hesperadin (0.3556 mg/kg; i.v.; once daily) contributed to some improvement of cardiac function, including an increase in LVEF and LVFS as well as a decrease in LVDd, LVDs, and left ventricular end‐systolic volume (LVESV) in myocardial ischemia/reperfusion injury (MIRI) mice.

Hesperadin hydrochloride purchased from MedChemExpress. Usage Cited in: Behav Neurol. 2020 Feb 3:2020:2476861. [Abstract]

Customer Validation
Administration of Hesperadin influences endogenous expression of MST4, pAKT, AKT, and LC3 12 h following ICH. Representative western blot bands for MST4, pAKT, AKT, and LC3 expression in sham and ICH mice 12 h following ICH.